In short
Clinical trials of ZILUCOPLAN are studying its safety, long-term tolerability, and how it works in people with generalized myasthenia gravis. The research includes children, teens, and adults, and some studies follow participants who already took part in earlier ZILUCOPLAN trials.
Key points
- ZILUCOPLAN clinical trials are studying generalized myasthenia gravis, mainly in children, teens, and adults. The studies are in Phase 3 and Phase 4, which means they focus on later-stage safety and longer-term follow-up. Some trials look at long-term safety and tolerability, while one pediatric study also measures how ZILUCOPLAN moves through the body and how it affects blood markers. The trials include participants who already finished earlier ZILUCOPLAN studies, as well as new pediatric and adult participants. The main results being measured are adverse events, serious adverse events, infections, and changes in disease scores or lab tests.
Overview of the studies
These clinical trials are studying ZILUCOPLAN in people with generalized myasthenia gravis (gMG), a disease that causes muscle weakness in several parts of the body.
The available trials focus on later stages of research, with Phase 3 and Phase 4 studies listed in the source data.
Across the trials, researchers are mainly looking at safety, long-term tolerability, and in some studies how ZILUCOPLAN behaves in the body and how it affects disease-related tests.
Who the trials include
One trial is for pediatric participants, meaning children and adolescents, and it includes patients from 2 to under 18 years of age with gMG.
Another pediatric study follows children who already took part in a previous ZILUCOPLAN study, so it is designed as a follow-up for earlier participants.
The adult extension study includes people with gMG who have already completed a qualifying ZILUCOPLAN clinical study.
One additional study listed in the data is a broader myasthenia gravis study that includes ZILUCOPLAN among many other treatments, but its main focus is not ZILUCOPLAN alone.
What the trials measure
The pediatric long-term safety study measures treatment-emergent adverse events (health problems that appear after treatment starts), serious adverse events, treatment stopping because of side effects, and infections.
The pediatric Phase 4 study measures plasma concentrations of ZILUCOPLAN, which means how much of the study drug is found in the blood, at Week 4.
That same study also measures change from baseline in sheep red blood cell (sRBC) lysis and complement component 5 (C5) levels at Week 4, which are laboratory tests used in the study to track biological effects.
The adult extension study measures the incidence of TEAEs, which helps show how often new side effects happen during follow-up treatment.
The broader study that lists ZILUCOPLAN among several treatments measures MG-ADL and QMG changes at 24 weeks in different phases, which are scores used to track daily function and muscle weakness in myasthenia gravis.
Trial phases and status
The pediatric safety follow-up study is in Phase 3 and is marked Authorised with an enrollment of 10 participants.
The pediatric study of blood levels and biological effects is in Phase 4, also marked Authorised, with an enrollment of 10 participants.
The adult long-term extension study is in Phase 3, is Authorised, and has a planned enrollment of 190 participants.
The broader study that includes ZILUCOPLAN alongside other treatments is listed as Phase 4, Authorised, with 66 participants.
Study details by trial
NCT06435312 is a long-term safety study in children with gMG who already joined a previous ZILUCOPLAN study. The brief summary says it is designed to assess safety and tolerability over an extra 52 weeks of daily subcutaneous treatment.
NCT06055959 studies how ZILUCOPLAN moves through the body over time and how safe it is in children with gMG. Its brief summary also says it looks at both pharmacokinetics and pharmacodynamics, which means it studies drug levels in the body and the body’s response to treatment.
NCT04225871 is an adult extension study that looks at long-term safety and tolerability in people with gMG who finished a qualifying ZILUCOPLAN study. Its only listed primary outcome is the incidence of TEAEs.
NCT06193889 is a broader study of anti-CD19 chimeric antigen receptor T-cell therapy in generalized myasthenia gravis, and it lists ZILUCOPLAN among several study drugs. Its primary outcomes in the source data focus on safety, MG-ADL change, and QMG change at 24 weeks for the main study treatment being tested.
What the results could show
These trials may help show whether ZILUCOPLAN can be used safely over time in children and adults with generalized myasthenia gravis.
They may also help researchers understand whether the treatment reaches the blood in expected amounts and whether it changes study markers linked to disease activity.
Because the studies are in later phases, they are especially focused on real patient experience, follow-up safety, and longer-term observation rather than early proof-of-concept testing.